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Introduction 
N-glycosylation is a common and yet complex posttranslational process that covalently links 
glycans (complex oligosaccharides) to proteins and lipids, affecting cellular structure and 
function. Glycans have important biological functions in protein maturation and turnover, cell 
adhesion and trafficking, and receptor binding and activation.1 In the immune system, 
glycosylation also modulates the function of immunoglobulin G (IgG). Differential N-
glycosylation of its fragment crystallisable (Fc) affects IgG effector functions through 
modified binding affinity to the Fc-receptors (FcyRs), enabling its ability to act as a pro- or 
anti-inflammatory agent.1 
Structural details of the attached glycans are of great physiological significance and many 
pathological conditions are associated with various types of glycan changes. Alterations in 
plasma protein glycosylation pathways with increased branching, galactosylation and 
sialylation are a hallmark of metabolic syndrome, cancers and inflammatory bowel diseases 
(IBD).1-2 Therefore, glycans have the potential to help stratify patients according to disease 
predisposition, prognosis, and response to treatment.1 For example, IBD patients with 
Crohn’s disease or ulcerative colitis have lower plasma levels of IgG galactosylation than 
healthy controls3 Furthermore, glycosylation patterns have been shown to be associated with 
IBD disease progression and need for surgery.3 
Certain members of the gut microbiota, such as Bacteroides and Bifidobacteria, are 
coevolved to thrive on host- and diet-derived glycans,4 where the former (B. fragilis) can 
efficiently deglycosylate complex N-linked glycans from the most abundant glycoproteins 
found in serum and serous fluid, thus conferring a competitive, nutritional advantage for 
extra-intestinal growth.5  However, it is not known if modulation of the gut microbiota via 
faecal microbiota transplantation (FMT) can affect the host’s glycosylation machinery, and if 
this may represent one mechanism by which FMT exerts its therapeutic efficacy against 
Clostridioides difficile infection (CDI), the leading infectious cause of antibiotic-associated 
diarrhea. Susceptibility to developing CDI typically occurs following disruption of the 
intestinal microbiota through antibiotic usage. While current treatment options include 
standard antibiotics and emerging immunologics, microbiome restoration approaches such 
as FMT are highly effective for the treatment of recurrent CDI (rCDI). Nevertheless, the 
precise mechanisms that underlie the success of FMT remain largely unclear with current 
evidence suggesting that its effectiveness in part, may be related to reconstitution of the 
intestinal microbiota, restoration of bile acid and short chain fatty acid metabolism, activation 
of immune-mediated mechanisms.6 Therefore, to address this gap in knowledge, we 
examined the composition of whole serum protein and subclass-specific IgG Fc N-glycome 
in subjects before and after FMT for rCDI. 
 
Methods 
For N-glycome profiling, we retrospectively analysed a subset of archived sera from rCDI 
participants successfully treated in two independent trials comparing capsule versus 
colonoscopy delivered FMT [NCT02254811; discovery cohort] and fresh versus frozen 
enema delivered FMT [NCT01398969; replication cohort] for treatment of rCDI. Sera were 
profiled for total serum and IgG Fc N-glycome analysis by hydrophilic interaction ultra-
performance liquid chromatography (HILIC-UPLC) and nano-liquid chromatography coupled 
with electrospray mass spectrometry (nanoLC-ESI-MS), respectively. For the discovery 
cohort, we evaluated 225 sera from 75 of 116 participants at screening, and compared with 
4 and 12 weeks’ post FMT. For the replication cohort, we assessed a total 110 sera from 55 
of 178 participants before and at one time point after FMT [median 31 days, (range 7-277 
days)] subject to sample availability. The baseline characteristics of both cohorts are 
illustrated in Supplementary Table 1. We analysed glycome changes for both cohorts 
individually and then aligned both discovery and replication data sets by comparing glycan 
signatures seen at the 4-week mark following FMT due to variability in sampling. Further 
details are described in the Supplementary Materials. 
Results 
In the discovery cohort, HILIC-UPLC analysis of the total serum N-glycome identified 11 
serum glycosylation structural features that changed significantly following FMT (Table 1). 
Specifically, we found a statistically significant increase in levels of low-branching, 
monosialylated, digalactosylated, oligomannose and bisecting N-acetylglucosamine glycans, 
while levels of high-branching, tri- and tetragalactosylated, tri- and tetrasialylated glycans 
and glycans with antennary fucosylation decreased following successful FMT. Meta-analysis 
confirmed that the effects of FMT were consistent across both the discovery and replication 
cohorts (Table 1). All 11 glycosylation traits that were significant in the discovery cohort 
remained significant in the meta-analysis of the combined studies.  
For IgG Fc N-glycopeptide analysis, none of the glycosylation traits showed statistically 
significant changes in either discovery or replication cohorts (Supplementary Table 2). There 
were also no specific differences in the relative abundance of the different total serum and 
IgG N-glycome traits with age, sex, treatment modality, number of recurrent episodes prior to 
FMT, presence of IBD or immune status in either cohort.  
In order to align the discovery and replication cohort sampling time points more evenly, we 
only selected sera that were collected around 4 weeks after FMT (n= 36 serum samples 
from 18 participants) in the replication cohort [median 31 days, (range 21-36)]. Here again, 
meta-analysis confirmed that 10 of 11 aforementioned serum glycan traits changed 
significantly and in the same direction to that seen for both cohorts.  
 
 Discussion 
This study represents the first exploratory analysis of whole serum and IgG N-glycosylation 
in participants undergoing FMT for rCDI. We demonstrate that successful FMT associates 
with a reduction in the complexity of serum N-glycosylation profiles, contrary to the complex 
glycophenotypes typically encountered in many pathological states such as IBD, type 2 
diabetes mellitus and cancer. Decreasing complexity of the serum N-glycome is mainly 
driven through a significant reduction in the relative abundance of high-branching, 
tetragalactosylated and trisialylated glycans and a corresponding increase in low-branching 
glycans. Although it is not known which specific cellular glycomic modifications occur 
following FMT, patients with autoimmune diseases and many inbred mouse strains display 
defective N-glycan branching on T cells, which may be restored by N-acetylglucosamine or 
vitamin D supplementation.7-8 In conclusion, changes in the complexity of N-glycans in sera, 
may serve as an important molecular mechanism by which FMT exerts its beneficial effects 
in rCDI. Future studies will be required to assess N-glycome patterns in the context of 
treatment failure in order to assess their prognostic relevance in predicting FMT outcomes in 
rCDI. 
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Supplementary Methods 
Patient clinical data, sample collection and storage 
Participants with recurrent CDI in the capsule versus colonoscopy (NCT02254811; n = 75 of 
116)1 and fresh versus frozen enema-delivered (NCT01398969; n= 55 of 178)2 FMT trials 
representing the discovery and replication cohorts respectively, were included in this study. 
Sera was separated from venous blood samples following centrifugation at 2200 g for 10 
minutes at room temperature. Serum aliquots were stored at -800C until ready for use. All 
archiving of sera was undertaken using standard operating protocols in the receiving centres 
which included labelling each sample with a study number and date of collection. Only 
serum samples with sufficient volume were selected for glycome profiling. For the derivation 
cohort, serum samples were collected over 26 months between October 2014 and 
December 2016 and stored at -800C in the biobank at the University of Alberta. The mean 
storage time before testing was 820.99 days (SD 180.78). Of these 75 patients, 227 
archived serum samples were available at screening, 4 and 12 weeks post-FMT and one 
case at two time points for capsule and colonoscopy for total serum and IgG Fc N-glycome 
profiling. For the validation cohort, serum samples were collected over 26 months between 
July 2012 and September 2014 at one time point following fresh or frozen FMT [median 31 
days, (range 7-277 days)]. The mean storage time before sample testing was 1869 days (SD 
233.57).  
Immunosuppression was defined as those on prednisolone (>5 mg/d), immunomodulators 
(azathioprine, methotrexate, calcineurin inhibitor) or biologics.  
Recurrent CDI cases were defined as having at least 2 episodes of CDI (NCT02254811) or  
at least 1 episode of CDI (NCT01398969) following an initial infection. Clinical and 
demographic information was collected from medical records. Participant baseline 
characteristics for both cohorts are shown in Supplementary Tables 1. Informed written 
consent was obtained from all participants, and ethical approval was provided by the Ethics 
Review Boards of the University of Alberta (Pro 1994 and 49006), and St Joseph’s Healthcare 
(#11-3622), Hamilton Health Sciences (#12-505). 
 
Glycome analysis 
Experimental design 
Participant serum samples and in-house serum standards were thawed, vortexed and 
centrifuged for 3 minutes at 12 100 g. Each sample (100 μL) was aliquoted to 2 mL 96-well 
collection plates (Waters, Milford, MA, USA) following a predetermined experimental design 
which included blocking of all known sources of variation (age, sex, time point, hospital) and 
sample randomization between the batches to reduce experimental error. In-house serum 
standards were aliquoted in seven to eight replicates per plate, to evaluate experimental error 
and integrity of generated data. An aliquot (10 μL) of each sample was transferred to 1 mL 96-
well collection plates (Waters, Milford, MA, USA) for N-glycome analysis and the rest was 
used for isolation of IgG followed by IgG Fc N-glycopeptide analysis. 
 
 
Serum N-glycome analysis 
Serum N-glycans were enzymatically released from proteins by PNGase F, fluorescently 
labelled with 2-aminobenzamide and cleaned-up from the excess of reagents by hydrophilic 
interaction liquid chromatography solid phase extraction (HILIC-SPE), as previously 
described.3 Fluorescently labelled and purified N-glycans were separated by HILIC on a 
Waters BEH Glycan chromatography column, 150 × 2.1 mm i.d., 1.7 μm BEH particles, 
installed on an Acquity ultra-performance liquid chromatography (UPLC) H-class system 
(Waters), consisting of a quaternary solvent manager, sample manager and a fluorescence 
detector set with excitation and emission wavelengths of 250 nm and 428 nm, respectively. 
Obtained chromatograms were separated into 39 peaks. The amount of N-glycans in each 
chromatographic peak was expressed as a percentage of total integrated area. From 39 
directly measured glycan peaks, we calculated 12 derived traits which average particular 
glycosylation traits such as galactosylation, sialylation and branching across different 
individual glycan structures and are, consequently, more closely related to individual 
enzymatic activities and underlying genetic polymorphisms. Derived traits used were the 
proportion of low branching (LB) and high branching (HB) glycans, the proportion of a-, mono-
, di-, tri- and tetra-galactosylated glycans (G0, G1, G2, G3 and G4, respectively), and a-, 
mono-, di-, tri- and tetra-sialylated glycans (S0, S1, S2, S3 and S4, respectively).   
 
IgG Fc N-glycopeptides analysis 
Sample preparation and analysis of IgG N-glycopeptides was done using a previously 
described protocol with minor changes.4 Briefly, IgG was isolated from 90 µL of serum samples 
by affinity chromatography using CIM® 96-well Protein G monolithic plate (BIA Separations, 
Ajdovščina, Slovenia). IgG N-glycopeptides were prepared by trypsin digestion of an aliquot 
of IgG isolates (25 μg on average per sample) followed by reverse-phase solid phase 
extraction (RP-SPE). Purified tryptic IgG N-glycopeptides were separated and measured on 
nanoAcquity chromatographic system (Waters) coupled to Compact Q-TOF mass 
spectrometer (Bruker, Bremen, Germany), equipped with Apollo II source and operated under 
HyStar software version 3.2.  
The first four isotopic peaks of doubly and triply charged signals, belonging to the same 
glycopeptide species, were summed together, resulting in 20 Fc N-glycopeptides per IgG 
subclass. Predominant allotype variant of IgG3 tryptic peptide carrying N-glycans in 
Caucasian population has the same amino acid sequence as IgG2.5 Therefore, IgG 
glycopeptides were separated into three chromatographic peaks labeled IgG1, IgG2/3 and 
IgG4. Signals of interest were normalised to the total area of each IgG subclass. 
 
 
 
Statistical analysis 
All statistical analyses were performed in SPSS v.24 and R 3.5.1. Descriptive statistics for 
patient characteristics at baseline were reported using mean and standard deviation, median 
and interquartile ranges and percentages. Prior to analyses, glycan variables were all 
transformed to standard normal distribution (mean = 0, sd = 1) by inverse transformation of 
ranks to Normality (R package “GenABEL”, function rn transform). Using rank transformed 
variables in analyses makes estimated effects of different glycans in different cohorts 
comparable as transformed glycan variables having the same standardized variance. 
Association analyses between N-glycome changes (through time) and clinical variables of 
interest were performed using a linear mixed model. Analyses were first performed for each 
cohort separately and then combined using inverse-variance weighted meta-analysis 
approach (R package metafor). False discovery rate was controlled using Benjamini-
Hochberg procedure.  
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